Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers. Our mission is to expand the reach of targeted therapeutics by developing products for underserved populations. We utilize our deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which we refer to as our Kinnate Discovery Engine, to develop targeted therapies. Headquartered in San Diego and San Francisco, the Kinnate team is composed of drug discovery experts supported by world-class scientific advisors and investors. For more information, please visit www.kinnate.com.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $207.5M
Founded date: 2018
Investors 5
| Date | Name | Website |
| 17.07.2020 | Logos Capi... | logoscapit... |
| - | Vida Ventu... | vidaventur... |
| - | Foresite C... | foresiteca... |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.05.2021 | Series A | $35M | - |
| 16.09.2020 | Series C | $98M | - |
| 29.12.2019 | Series B | $74.5M | - |
Mentions in press and media 23
| Date | Title | Description |
| 05.06.2024 | Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations | CASTRES, France, June 5, 2024 /PRNewswire/ -- Pierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to initiate a first-i... |
| 09.03.2024 | INVESTIGATION UPDATE: Halper Sadeh LLC Investigates CTLT, EVBG, FREE, KNTE | - |
| 01.03.2024 | Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories | Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction is in furtherance of Kinnate's previously announced ... |
| 18.05.2021 | Kinnate Biopharma Joint Venture Raises Usd35 Million in Series A Financing | Kinnate Biopharma Inc. has raised USD 35 million Series A financing for a joint venture in China. The financing was led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital. Kinnate Biopharma wi... |
| 13.05.2021 | Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture | - |
| 13.05.2021 | KINNATE BIOPHARMA INC. Kinnate Biopharma Inc :. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture | Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital The joint venture will have exclusive license to develop and commercialize Kinnate’s currently most advanced kinase inhibitor c... |
| 25.02.2021 | Biotech and healthtech firm Foresite Capital raises $969M new fund | The firm, which now has over $4 billion in assets under management, invests across all stages The biotech space has been growing in the last few years: according to Pitchbook, the space was on track to see more than $20 billion invested in ... |
| 17.11.2020 | Kinnate Biopharma Files For $100M IPO | San Diego-based Kinnate Biopharma has filed for an IPO, saying in a filing that it is looking to raise up to $100M. The company has filed to trade on the Nasdaq Global Select Market under the symbol KNTE. The IPO is being underwritten by Go... |
| 28.08.2020 | Kinnate Biopharma Closes $98M Series C Financing | Kinnate Biopharma Inc., a San Diego, Calif.-based biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, raised $98m in a Series C financin... |
| 28.08.2020 | Kinnate Biopharma Closes $98M Series C Financing | Kinnate Biopharma Inc., a San Diego, Calif.-based biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, raised $98m in a Series C financin... |
Show more